Advani R et al. Stage I and II follicular non-Hodgkin’s lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol 2004;22(8):1454-9. Abstract

George S et al. Fixed-dose pegfilgrastim is safe and allows neotrophil recovery in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44(10);1691-6. Abstract

Ghielmini M et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103(12):4416-23. Abstract

Grigg A et al. Open-label, randomized study of pegfilgrastim vs daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44(9):1503-8. Abstract

Hainsworth JD et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin’s lymphoma: A Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23(7);[Epub ahead of print]. Abstract

Honecker F et al. Chemotherapy in elderly patients with advanced lung cancer. Part I: General aspects and treatment of small cell lung cancer (SCLC). Onkologie 2004;27(5):500-5. Abstract.

Marcus R et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma. Proc ASH 2003;Abstract 87.

Marcus R et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2004;[Epub ahead of print]. Abstract

Morrison VA et al. A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients. J Clin Oncol 2004;22(14S):Abstract 8068.

Ozer H et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 2000;18(20):3558-85. No abstract available

Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003;1(s2):18-24. Abstract

Vose JM et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21(3):514-9. Abstract